Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658092 | 0.85 | CYP2D6 (0.37) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL4913030 | 0.82 | CHRNB2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL5654809 | 0.81 | FFAR1 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL3728065 | 0.80 | CYP2A6 (0.54) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL28089 | 0.78 | — | — | |
| SCHEMBL3723301 | 0.73 | NOS3 (0.42) | — | |
| SCHEMBL8730197 | 0.73 | NPSR1 (0.31) | — | |
| SCHEMBL17050214 | 0.73 | GRM5 (0.48) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3244440 | 0.71 | GRM5 (0.55) | CYP2C9CYP2C19CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL28077 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064118-B2 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2006-06-20 | — | — | US | claimed |
| US-20060100192-A1 | Heteroaryl diazacycloalkanes, their preparation and use | DANPET AB (SE) | 2006-05-11 | — | — | US | claimed |
| US-20020045618-A1 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | US | claimed |
| US-7282494-B2 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2007-10-16 | — | — | US | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7064118-B2 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2006-06-20 | — | — | US | disclosed |
| US-20060100192-A1 | Heteroaryl diazacycloalkanes, their preparation and use | DANPET AB (SE) | 2006-05-11 | — | — | US | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-20020045618-A1 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | US | disclosed |
| EP-1175416-A1 | HETEROARYL DIAZACYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000064885-A1 | HETEROARYL DIAZACYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045618-A1 | Heteroaryl diazacycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA3 | CHRNB2 7/4885CHRNA4 12/4885CYP2A6 441/4885 |
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | CHRNB2 276/4885CHRNA4 111/4885CYP2A6 2174/4885 |
| US-20060100192-A1 | Heteroaryl diazacycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA3 | CHRNB2 10/4885CHRNA4 9/4885CYP2A6 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.